At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Minocycline, Placebo, and 1 other intervention for Lung Cancer. Completed, enrolled 51 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if minocycline can reduce the side effects reported by patients with NSCLC who are receiving chemoradiation therapy. In this study, minocycline will be compared to a placebo. Minocycline is an antibiotic that may help to reduce side effects of chemoradiation therapy. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
Study Details
Timeline
Interventions
100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.